Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Impact of introduction of angiotensin II antagonist on the antihypertensive utilization in Taiwan

View through CrossRef
This study aimed to evaluate the long term impact of a new pharmacological class antihypertensive medicine-angiotensin II antagonist (AIIA) on the clinical utilization of existing antihypertensive medications in Taiwan. Claims data of medical service and prescriptions of antihypertensive agents during 1997 to 2002 were obtained from National Health Insurance Research Database (NHIRD). Gross growth of defined daily dose (DDD) and prescription numbers, clinical market share and prescription market share analysis, market penetration time and DDDs/prescription were used to assess AIIA's impact on the angiotensin converting enzyme inhibitors (ACEI), β-Blockers, calcium channel blockers (CCB) and other miscellaneous antihypertensive agents. CCB had the highest gross growth of DDDs and prescription at 117.1 and 3.4 million increments, respectively. Analysis of clinical market share revealed that the introduction of AIIA had the most significant impact to the clinical utilization of miscellaneous antihypertensive agents (5.5%) and a moderate impact on both B-blockers (4.5%) and ACEI (4.1%). Whereas the greatest impact of prescription market share was observed with miscellaneous antihypertensive agents (-6.5%), a moderate impact with ACEI (-2.3%) and a very minor impact with β-blockers (0.9%). CCB, however, had a positive clinical market share (+3.9%) and prescription market share (+2.4%) correlated with AIIA. AIIA utilization implicated by relative growth strength for the clinical market share and prescription market share at medical center, regional hospital, district hospital and primary care clinic were 4.95:3.77:2.77:1 and 5.28:4.17:2.94:1, respectively. The introduction of AIIA did not affect the decreasing trend of clinical utilization of miscellaneous antihypertensive agents and β-blockers since this downtrend started before AIIA introduction. On the other hand, there was increasing usage of CCB and AIIA to control hypertension in Taiwan. Medical centers were the early adaptors for AIIA and played an important role in the utilization diffusion of AIIA.
The Journal of Food and Drug Analysis (JFDA), Food and Drug Administration, Taiwan (TFDA)
Title: Impact of introduction of angiotensin II antagonist on the antihypertensive utilization in Taiwan
Description:
This study aimed to evaluate the long term impact of a new pharmacological class antihypertensive medicine-angiotensin II antagonist (AIIA) on the clinical utilization of existing antihypertensive medications in Taiwan.
Claims data of medical service and prescriptions of antihypertensive agents during 1997 to 2002 were obtained from National Health Insurance Research Database (NHIRD).
Gross growth of defined daily dose (DDD) and prescription numbers, clinical market share and prescription market share analysis, market penetration time and DDDs/prescription were used to assess AIIA's impact on the angiotensin converting enzyme inhibitors (ACEI), β-Blockers, calcium channel blockers (CCB) and other miscellaneous antihypertensive agents.
CCB had the highest gross growth of DDDs and prescription at 117.
1 and 3.
4 million increments, respectively.
Analysis of clinical market share revealed that the introduction of AIIA had the most significant impact to the clinical utilization of miscellaneous antihypertensive agents (5.
5%) and a moderate impact on both B-blockers (4.
5%) and ACEI (4.
1%).
Whereas the greatest impact of prescription market share was observed with miscellaneous antihypertensive agents (-6.
5%), a moderate impact with ACEI (-2.
3%) and a very minor impact with β-blockers (0.
9%).
CCB, however, had a positive clinical market share (+3.
9%) and prescription market share (+2.
4%) correlated with AIIA.
AIIA utilization implicated by relative growth strength for the clinical market share and prescription market share at medical center, regional hospital, district hospital and primary care clinic were 4.
95:3.
77:2.
77:1 and 5.
28:4.
17:2.
94:1, respectively.
The introduction of AIIA did not affect the decreasing trend of clinical utilization of miscellaneous antihypertensive agents and β-blockers since this downtrend started before AIIA introduction.
On the other hand, there was increasing usage of CCB and AIIA to control hypertension in Taiwan.
Medical centers were the early adaptors for AIIA and played an important role in the utilization diffusion of AIIA.

Related Results

Pharmacogenomics and the Concept of Personalized Medicine for the Management of Hypertension
Pharmacogenomics and the Concept of Personalized Medicine for the Management of Hypertension
Hypertension poses a significant global burden due to low adherence to antihypertensive medications. Hypertension treatment aims to bring blood pressure within physiological ranges...
Development of angiotensin (1‐7) as an agent to accelerate dermal repair
Development of angiotensin (1‐7) as an agent to accelerate dermal repair
Angiotensin II has been shown to be a potent agent in the acceleration of wound repair. Angiotensin (1‐7), a fragment of angiotensin II that is not hypertensive, was found to be co...
From Big Data to Mask Diplomacy: Taiwan’s Effort to Strengthen International Role
From Big Data to Mask Diplomacy: Taiwan’s Effort to Strengthen International Role
Dengan mengandalkan ketahanan domestik tanpa dukungan komunitas internasional, Taiwan yang terkucil dari pergaulan dunia berhasil mengendalikan pandemi COVID-19. Meskipun Taiwan me...
Abstract 125: Modified Angiotensin II Has Lower Vasoconstrictive Effect Than Angiotensin II
Abstract 125: Modified Angiotensin II Has Lower Vasoconstrictive Effect Than Angiotensin II
Introduction: The renin-angiotensin-aldosterone system (RAAS) is involved in the regulation of the blood pressure, water- and electrolyte balance. Pathophysiologically,...
Characterization of Contractile Response to Angiotensin in Epididymal Rat Vas deferens
Characterization of Contractile Response to Angiotensin in Epididymal Rat Vas deferens
Angiotensin had a dual action on the epididymal half of rat vas deferens. It potentiated electrical stimulated contraction and exerted a direct contractile effect on the muscle. Th...
MO093CLARIFICATION OF BIOSYNTHESIS OF ANGIOPROTECTIN
MO093CLARIFICATION OF BIOSYNTHESIS OF ANGIOPROTECTIN
Abstract Background and Aims The renin-angiotensin-aldosterone system (RAAS) is involved in the regulation of the blood pressure...
Angiotensins
Angiotensins
Abstract The sections in this article are: Angiotensin Generation and Metabolism ...
Angiotensin II Induces Oxidative Stress in Prostate Cancer
Angiotensin II Induces Oxidative Stress in Prostate Cancer
Abstract Angiotensin II has been shown to be a cytokine especially acting as a growth factor. A local renin-angiotensin system has been identified in the prostate gl...

Back to Top